As Alexion Pharmaceuticals (ALXN) Share Value Declined, Palo Alto Investors Boosted Position; Capital Counsel Decreased Its Holding in Cme Group Com (CME) as Stock Declined

February 18, 2018 - By Stephen Andrade

Capital Counsel Llc decreased its stake in Cme Group Inc Com (CME) by 0.62% based on its latest 2017Q3 regulatory filing with the SEC. Capital Counsel Llc sold 5,570 shares as the company’s stock declined 4.72% while stock markets rallied. The institutional investor held 899,753 shares of the investment bankers and brokers and service company at the end of 2017Q3, valued at $122.08M, down from 905,323 at the end of the previous reported quarter. Capital Counsel Llc who had been investing in Cme Group Inc Com for a number of months, seems to be less bullish one the $55.26B market cap company. The stock decreased 1.65% or $2.73 during the last trading session, reaching $162.38. About 1.45M shares traded. CME Group Inc. (NASDAQ:CME) has risen 25.35% since February 18, 2017 and is uptrending. It has outperformed by 8.65% the S&P500.

William Leland Edwards increased its stake in Alexion Pharmaceuticals Inc (ALXN) by 4.79% based on its latest 2017Q3 regulatory filing with the SEC. Palo Alto Investors Llc bought 49,400 shares as the company’s stock declined 11.63% while stock markets rallied. The hedge fund run by William Leland Edwards held 1.08 million shares of the health care company at the end of 2017Q3, valued at $151.56 million, up from 1.03M at the end of the previous reported quarter. Palo Alto Investors Llc who had been investing in Alexion Pharmaceuticals Inc for a number of months, seems to be bullish on the $26.71B market cap company. The stock decreased 1.83% or $2.24 during the last trading session, reaching $120.47. About 3.90M shares traded or 81.87% up from the average. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 18.12% since February 18, 2017 and is downtrending. It has underperformed by 34.82% the S&P500.

Since August 28, 2017, it had 0 insider purchases, and 14 insider sales for $6.68 million activity. The insider O’Neill Julie sold 4,787 shares worth $556,776. Shares for $121,751 were sold by Veneman Ann M. Clancy Paul J sold $707,048 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Tuesday, February 6. $147,865 worth of stock was sold by Moriarty John B on Monday, February 5. On Monday, February 5 Wagner Heidi L sold $76,805 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) or 655 shares. $169,696 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares were sold by Franchini Indrani Lall.

Among 29 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), 24 have Buy rating, 0 Sell and 5 Hold. Therefore 83% are positive. Alexion Pharmaceuticals Inc. had 100 analyst reports since July 27, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Friday, July 31 by Brean Capital. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Buy” rating by Stifel Nicolaus on Thursday, February 8. The rating was initiated by BMO Capital Markets with “Market Perform” on Thursday, April 7. Robert W. Baird maintained it with “Hold” rating and $145.0 target in Tuesday, September 12 report. The firm earned “Buy” rating on Thursday, February 4 by UBS. The firm has “Outperform” rating by Leerink Swann given on Friday, July 28. As per Monday, June 27, the company rating was upgraded by Citigroup. The rating was maintained by Cowen & Co with “Buy” on Thursday, July 27. Barclays Capital upgraded Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Tuesday, November 29 to “Overweight” rating. The stock has “Buy” rating by BMO Capital Markets on Friday, October 20.

Palo Alto Investors Llc, which manages about $1.30 billion and $2.37B US Long portfolio, decreased its stake in United Therapeutics Corp Del (NASDAQ:UTHR) by 104,665 shares to 1.76M shares, valued at $206.57 million in 2017Q3, according to the filing. It also reduced its holding in Vanda Pharmaceuticals Inc (NASDAQ:VNDA) by 47,600 shares in the quarter, leaving it with 4.16M shares, and cut its stake in Abiomed Inc (NASDAQ:ABMD).

Investors sentiment decreased to 1.17 in Q3 2017. Its down 0.20, from 1.37 in 2017Q2. It dropped, as 36 investors sold ALXN shares while 174 reduced holdings. 78 funds opened positions while 167 raised stakes. 206.89 million shares or 0.54% less from 208.01 million shares in 2017Q2 were reported. Amalgamated Bancshares holds 26,086 shares. Bb&T Securities Limited holds 0.01% or 3,381 shares in its portfolio. Mark Sheptoff Fin Planning Ltd Liability Company has 0.01% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Texas-based Next Financial Group has invested 0.01% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Calamos Advisors Lc reported 290,711 shares. Alexandria Cap Ltd Limited Liability Company accumulated 0% or 43 shares. Daiwa Secs Group Inc reported 0.01% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Proshare Advisors Limited Liability Company holds 0.27% or 208,206 shares in its portfolio. Retirement System Of Alabama holds 0.12% or 168,380 shares. World Asset Mgmt invested in 0.1% or 20,883 shares. 4,844 are owned by At State Bank. San Francisco Sentry Inv Grp Incorporated (Ca) reported 0% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Canada Pension Plan Investment Board holds 0.11% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 392,696 shares. Geode Cap Mgmt Limited Co has 2.19 million shares for 0.11% of their portfolio. Dupont Cap Mngmt stated it has 1,111 shares or 0% of all its holdings.

Since August 28, 2017, it had 0 insider purchases, and 11 selling transactions for $9.48 million activity. Sammann Derek sold $387,972 worth of CME Group Inc. (NASDAQ:CME) on Friday, February 2. Another trade for 16,105 shares valued at $2.61 million was made by Kometer Kevin on Friday, February 2. Shares for $97,005 were sold by Suskind Dennis on Monday, September 11. On Monday, December 18 the insider Tobin Jack J sold $354,051. $186,300 worth of CME Group Inc. (NASDAQ:CME) was sold by Piell Hilda Harris on Thursday, October 5. 850 shares were sold by GLICKMAN DANIEL R, worth $107,653 on Monday, August 28.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Stephen Andrade

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: